| LICENSEES |
LICENSEES |
92%
|
The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents |
| COSETTE |
COSETTE |
90%
|
Under that Asset Purchase Agreement, Assertio assigned and transferred its rights and certain obligations arising post closing to Cosette. Cosette assumed the intellectual property license and rights… |
| INDIVIOR |
INDIVIOR |
90%
|
For the three months ended March 31, 2026, Indivior and Zevra, represented approximately 57 % and 32 %, of total revenue, respectively. |
| ZEVRA |
ZEVRA |
90%
|
For the three months ended March 31, 2026, Indivior and Zevra, represented approximately 57 % and 32 %, of total revenue, respectively. |
| ASRT |
Assertio Holdings, Inc. |
85%
|
Reciprocal relationship from ASRT graph: Reciprocal relationship from AQST graph: anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanov… |
| ASRT |
Assertio Holdings, Inc. |
85%
|
anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanovia Amendment No. 1. • Sympazan ® – an oral soluble film formulation of clobazam us… |
| ASSERTIO |
ASSERTIO |
85%
|
As of March 31, 2026, Indivior and Assertio exceeded the 10% threshold for outstanding receivable balances and represented approximately 81 % and 15 % of total trade and other receivables, respectively. |
| HYPERA |
HYPERA |
85%
|
For the three months ended March 31, 2025, Indivior and Hypera exceeded the 10% threshold for revenue and represented approximately 67 % and 17 % of total revenue, including the one-time recognition … |
| ZVRA |
Zevra Therapeutics, Inc. |
85%
|
Reciprocal relationship from ZVRA graph: Reciprocal relationship from AQST graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from AQST graph: Reciprocal relationship from ZVRA g… |
| CALIFORNIA-LITIGATION-NEURELIS-INC |
CALIFORNIA-LITIGATION-NEURELIS-INC |
62%
|
term (years) 6.1 Risk-free interest rate 3.8 % The weighted average grant date fair value of stock options granted during the three months ended March 31, 2026 was $ 3.43 . During the three months en… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
in the aggregate principal amount of $45,000 plus fees associated with the repayment. See Note 21, Subsequent Events to the accompanying Condensed Financial Statements. 43 Table of Contents Three Mon… |
| CYNAPSUS-THERAPEUTICS-INC |
CYNAPSUS-THERAPEUTICS-INC |
62%
|
anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanovia Amendment No. 1. • Sympazan ® – an oral soluble film formulation of clobazam us… |
| K-SMALLER-REPORTING-COMPANY |
K-SMALLER-REPORTING-COMPANY |
62%
|
anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanovia Amendment No. 1. • Sympazan ® – an oral soluble film formulation of clobazam us… |
| NEURELIS-FDA-LAWSUIT-NEURELIS-INC |
NEURELIS-FDA-LAWSUIT-NEURELIS-INC |
62%
|
term (years) 6.1 Risk-free interest rate 3.8 % The weighted average grant date fair value of stock options granted during the three months ended March 31, 2026 was $ 3.43 . During the three months en… |
| OTTER-PHARMACEUTICALS-LLC |
OTTER-PHARMACEUTICALS-LLC |
62%
|
anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanovia Amendment No. 1. • Sympazan ® – an oral soluble film formulation of clobazam us… |
| RECKITT-BENCKISER-PHARMACEUTICALS-INC |
RECKITT-BENCKISER-PHARMACEUTICALS-INC |
62%
|
istorical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on no less than a quarterly basis. The following table… |
| RESEARCH-FEES-CO |
RESEARCH-FEES-CO |
62%
|
her development or other ongoing activities by us, our licensee has acquired the right to use the licensed intellectual property for self-development of their product candidate, for manufacturing, co… |
| SUNOVION-PHARMACEUTICALS-INC |
SUNOVION-PHARMACEUTICALS-INC |
62%
|
istorical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on no less than a quarterly basis. The following table… |
